<DOC>
	<DOCNO>NCT01830101</DOCNO>
	<brief_summary>The investigator hope improve overall median survival patient recurrent Glioblastoma investigate continuous low-dose daily Temozolomide plus minus five treatment re-irradiation .</brief_summary>
	<brief_title>A Phase III Study Re-Irradiation Recurrent Glioblastoma</brief_title>
	<detailed_description>This stratify study patient recurrent intracranial glioblastoma gliosarcoma previously treat concurrent chemoradiation present radiographic progression recurrence tumour . Patients stratify extent resection , time re-irradiation re-irradiation volume .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>histologicallyproven intracranial glioblastoma gliosarcoma previously treat concurrent chemoradiation radiographic evidence tumour progression recurrence 18 year old ECOG 0 2 sign inform consent form tumour progression recurrence within 3 month initial concurrent chemoradiation 6 cycle TMZ administer follow chemoradiation initial diagnosis one prior course salvage chemo recurrent disease prior invasive malignancy ( except nonmelanomatous skin cancer ) unless disease free great equal 3 year prior head neck RT except T1 glottic cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>recurrent glioblastoma</keyword>
	<keyword>re-irradiation</keyword>
	<keyword>continuous low-dose temozolomide</keyword>
</DOC>